MGI Tech 华大智造
China · Shenzhen
alternative to Illumina
DNBSEQ short-read gene sequencers, from the benchtop E25 and G99 to the high-throughput T7 and T20, CycloneSEQ nanopore long-read sequencers, and library-prep automation and reagents. Sequencers for Europe are also built at its plant in Riga, Latvia.
Why it fits
- Gene Sequencing
- Cost-effective
Regional alternatives
Product facts
- Segment
- Gene Sequencing
- Role
- Manufacturer
H1 2026 interim report (Aug 2026): revenue CNY 1.34B (+19%). In Feb 2026 MGI agreed to sell its US subsidiary Complete Genomics to Swiss Rockets AG and license it DNBSEQ (StandardMPS) technology for the US and Canada; closing not confirmed.
Market authorizations
European Union
Verified records only; absence here does not mean a product is unauthorized.
Regulatory & supply-chain notes
US DoD Section 1260H list
MGI Tech is on the list, which also makes it a “biotechnology company of concern” under the BIOSECURE Act.
MGI Tech Co., Ltd. · company listed · as of 2026-10 · source ↗
A list of “Chinese military companies”. Since 30 June 2026 the Department of Defense may not contract with listed companies; from 30 June 2027 that extends to goods and services that include their products. It does not restrict anyone else buying or using the product.
Company & market
- Parent company
- MGI Tech (BGI Group)
- Registered
- Shenzhen
- Listing
- A-share
- Ticker
- 688114.SS
- Market cap / val. (USD)
- ~$3.6 B
- Foreign-investable
- No